Pascal Soriot, AstraZeneca (AP Images)
April 16, 2020 10:26 AM EDT
People

Pas­cal So­ri­ot, lamenter of low pay, faces in­vestor re­volt for be­ing over­com­pen­sat­ed

Jason Mast

Editor

As­traZeneca CEO Pas­cal So­ri­ot once be­moaned his $13 mil­lion an­nu­al salary, call­ing him­self the “low­est-paid CEO in the whole in­dus­try.”

Now, af­ter his new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times